Learn more →
Back to Expert Scholars
Immunotherapy / 免疫治疗Cancer Immunology

Marco Colonna

马可·科隆纳

MD

🏢Washington University School of Medicine in St. Louis(圣路易斯华盛顿大学医学院)🌐USA

Robert Rock Belliveau MD Professor of Pathology; Head, Division of Immunobiology病理学罗伯特·罗克·贝利沃讲席教授;免疫生物学部门主任

130
h-index
2
Key Papers
5
Awards
3
Key Contributions

👥Biography 个人简介

Marco Colonna at Washington University St. Louis is a leading figure in innate immune cell biology. He discovered DAP12, defined innate lymphoid cell (ILC) subsets, and characterized TREM receptor families, providing foundational knowledge of NK and ILC biology relevant to innate anti-tumor immunity and myeloid immunosuppression in cancer.

Share:

🧪Research Fields 研究领域

Innate Lymphoid Cells先天淋巴样细胞
NK Cell BiologyNK细胞生物学
DAP12 SignalingDAP12信号传导
TREM ReceptorsTREM受体
Tumor Innate Immunity肿瘤先天免疫

🎓Key Contributions 主要贡献

Discovery of DAP12 and ITAM-Based NK Signaling

Discovered DAP12, a key signaling adaptor for multiple NK cell activating receptors including NKp44 and KIR, establishing the ITAM-based signaling framework for NK cell activation and cytotoxicity against tumor targets.

Innate Lymphoid Cell Classification

Contributed foundational work classifying ILC subsets (ILC1, ILC2, ILC3) by transcriptional programs and cytokine profiles, enabling precise study of which ILC populations promote or suppress anti-tumor immunity.

TREM2 in Tumor-Associated Macrophages

Identified TREM2 as a marker of immunosuppressive tumor-associated macrophages and showed that TREM2 blockade reduces TAM immunosuppression and synergizes with anti-PD-1 to improve anti-tumor responses.

Representative Works 代表性著作

[1]

A novel family of diverse co-stimulatory receptors in humans and mice that signal through the adaptor TYROBP (DAP12)

Journal of Experimental Medicine (1999)

Discovery paper characterizing DAP12 as an ITAM-containing adaptor for a family of NK activating receptors, establishing a central signaling paradigm in innate cytotoxic immunity.

[2]

TREM2 sustains macrophage-tumor crosstalk and restricts anti-tumor immunity

Cell (2019)

Showed that TREM2+ tumor-associated macrophages are immunosuppressive and that TREM2 blockade enhances checkpoint immunotherapy responses in preclinical models.

🏆Awards & Recognition 奖项与荣誉

🏆AAI-BD Biosciences Investigator Award
🏆Member, National Academy of Sciences
🏆Member, American Academy of Arts and Sciences
🏆AACR Outstanding Achievement Award in Cancer Immunology
🏆Fellow, American Association of Immunologists

📄Data Sources 数据来源

Last updated: 2026-01-15 | All information from publicly available academic sources

关注 马可·科隆纳 的研究动态

Follow Marco Colonna's research updates

留下邮箱,当我们发布与 Marco Colonna(Washington University School of Medicine in St. Louis)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment